Bacterial Gastroenteritis Follow-up

  • Author: Jennifer Lynn Bonheur, MD; Chief Editor: Julian Katz, MD   more...
 
Updated: Apr 15, 2011
 

Further Inpatient Care

  • Admit neonates or young infants with moderate dehydration, suspected infection with enterohemorrhagic E coli, or bloody diarrhea.
  • Oral rehydration in cases of gastroenteritis is a time-consuming task that requires vigilance. Evaluate the caretaker of a child who requires oral rehydration for compliance. Consider admission if any doubt in potential compliance exists.
  • Older patients, often with other illnesses, require careful observation and consideration for admission.
Next

Further Outpatient Care

  • Follow-up care in cases of bacterial gastroenteritis depends on the severity of the infection and the age of the patient.
    • Uncomplicated diarrhea may not require follow-up if the patient or caretaker is reliable and has adequate access to medical care if needed.
    • Monitor young children, elderly patients, and debilitated individuals closely to ensure complications do not occur.
    • Monitor patients requiring labor-intensive oral rehydration to ensure that the proper diet has been reintroduced.
    • Neonates require strict follow-up care within a few days of illness to ensure that malabsorption and dehydration do not occur.
Previous
Next

Deterrence/Prevention

  • Salmonella typhi vaccine is recommended for travelers to countries with a high incidence of this infection, persons with intimate exposure to a documented typhoid fever carrier, and workers with frequent exposure to these bacteria. Live attenuated, killed whole-cell, and capsular polysaccharide vaccines are available.
  • Vibrio vaccine is available but only protects 50% of immunized persons for 3-6 months. It is not indicated for widespread use.
  • In February 2006, the United States Food and Drug Administration (FDA) approved an oral vaccine for rotavirus (RotaTeq) for use in infants. It is currently the only vaccine approved in the United States for the prevention of rotavirus gastroenteritis as of the date of this publication. On February 21, 2006, the American Academy of Pediatrics (AAP) and the Advisory Committee on Immunization Practices (ACIP) recommended RotaTeq to be part of regularly scheduled childhood immunizations. RotaTeq is administered in a 3-dose series starting between age 6 to 12 weeks and completing before age 32 weeks.Clinical trials demonstrated prevention of 74% of all rotavirus gastroenteritis cases, of nearly all severe rotavirus gastroenteritis cases, and of nearly all hospitalizations. Previously marketed rotavirus vaccine (RotaShield) was associated with intussusception, but RotaTeq did not show an increased risk compared with placebo in clinical trials.
  • In April 2008, the FDA approved Rotarix, another oral vaccine, for prevention of rotavirus gastroenteritis. Rotarix administration is currently recommended as 2 separate doses to patients between age 6 and 24 weeks. Rotarix was efficacious in a large study showing that it protected patients with severe rotavirus gastroenteritis as well as decreasing the rate of severe diarrhea or gastroenteritis of any cause.[18]
  • Avoidance of undercooked meats and seafood, as well as contaminated water supplies, when traveling may help reduce the risk of transmission of food and water-borne infectious causes of gastroenteritis and associated symptoms.
Previous
Next

Complications

  • Common complications that can occur with various organisms in cases of bacterial gastroenteritis are as follows:
    • Aeromonas caviae - Intussusception, gram-negative sepsis, and HUS
    • Bacillus species - Fulminant liver failure (very rare) and rhabdomyolysis (very rare)
    • Campylobacter species - Bacteremia, meningitis, cholecystitis, urinary tract infection, pancreatitis, and Reiter syndrome
    • C difficile - Chronic diarrhea, toxic megacolon, and ileus
    • C perfringens serotype C - Enteritis necroticans
    • Enterohemorrhagic E coli - Hemorrhagic colitis
    • Enterohemorrhagic E coli O157:H7 - HUS
    • Listeria species - Bacteremia and meningitis
    • Plesiomonas species - Septicemia
    • Salmonella species - Enteric fever, bacteremia, meningitis, osteomyelitis, myocarditis, and Reiter syndrome
    • Shigella species - Seizures, HUS, perforation, and Reiter syndrome
    • Vibrio species - Rapid dehydration
    • Yersinia enterocolitica - Appendicitis, perforation, intussusception, peritonitis, toxic megacolon, cholangitis, bacteremia, and Reiter syndrome
  • S typhi causes enteric fever. This syndrome has an insidious onset of malaise, fever, abdominal pain, and bradycardia. Diarrhea and rash (rose spots) appear after 1 week of symptoms. Bacteria may have disseminated at that time, and treatment is required to prevent systemic complications, such as hepatitis, myocarditis, cholecystitis, or gastrointestinal bleeding.
  • Damage to vascular endothelial cells by verotoxin causes HUS. Thrombocytopenia, microangiopathic hemolytic anemia, and acute renal failure are characteristic of HUS. Symptoms usually develop 1 week after onset of diarrhea, when organisms may be absent.
  • Reiter syndrome can complicate acute infections. Arthritis, urethritis, conjunctivitis, and mucocutaneous lesions are characteristic. Affected individuals usually do not demonstrate all features.
  • Carrier states are observed after some bacterial gastroenteritis infections. After Salmonella diarrhea, 1-4% of individuals with nontyphoid and enteric fever infections become carriers. Carrier stage for Salmonella species is more likely to develop in females, infants, and individuals with biliary tract disease. Asymptomatic C difficile carriage may be seen in many hospitalized patients receiving antibiotics and in 50% of infants.
  • Hyponatremic seizures can be avoided by rehydrating with oral rehydration solution instead of free water.
  • A study suggested that infectious gastroenteritis may play a role in the initiation and/or exacerbation of inflammatory bowel disease.[19] Similarly, irritable bowel syndrome may develop more often following bacterial gastroenteritis. This topic is highly controversial, and no conclusive evidence currently exists to support or refute this hypothesis.
Previous
Next

Prognosis

  • With proper management, prognosis is very good, especially in developed countries.
  • Mortality predominantly is due to dehydration and secondary malnutrition from a protracted course. Treat severe dehydration with parenteral fluids.
  • Once malnutrition from secondary malabsorption begins, prognosis becomes grim unless the patient is hospitalized and supplemental parenteral nutrition is started.
  • Neonates and young infants are at particular risk for dehydration, malnutrition, and malabsorption syndromes.
  • Even though the mortality rate is low in developed countries, people can, and do, die from complications. Prognosis in countries without modern medical care or for patients with serious preexisting medical conditions is more guarded.
Previous
Next

Patient Education

  • Education is most important for prevention and treatment of bacterial gastroenteritis.
  • Proper oral rehydration therapy helps to prevent dehydration and speed recovery of the intestinal mucosa.
  • Diet restrictions that prevent secondary malabsorption are extremely important; relapse typically occurs due to diet noncompliance.
  • Emphasize proper hygiene and food preparation practices to caretakers in order to prevent future infections and spread of bacterial gastroenteritis.
Previous
 
Contributor Information and Disclosures
Author

Jennifer Lynn Bonheur, MD  Attending Physician, Division of Gastroenterology, Lenox Hill Hospital

Jennifer Lynn Bonheur, MD is a member of the following medical societies: American Gastroenterological Association, American Society for Gastrointestinal Endoscopy, New York Academy of Sciences, New York Society for Gastrointestinal Endoscopy, and Sigma Xi

Disclosure: Nothing to disclose.

Coauthor(s)

Mukul Arya, MD  Associate Professor of Internal Medicine, Assistant Director of Therapeutic Endoscopy, Department of Gastroenterology and Internal Medicine, Wyckoff Heights Medical Center/Weill Medical College

Mukul Arya, MD is a member of the following medical societies: American College of Gastroenterology, American College of Physicians, American Gastroenterological Association, American Medical Association, and American Society for Gastrointestinal Endoscopy

Disclosure: Nothing to disclose.

Richard E Frye, MD, PhD  Assistant Professor, Departments of Pediatrics and Neurology, University of Texas Health Science Center at Houston

Richard E Frye, MD, PhD is a member of the following medical societies: American Academy of Neurology, American Academy of Pediatrics, Child Neurology Society, and International Neuropsychological Society

Disclosure: Nothing to disclose.

M Akram Tamer, MD  Program Director, Professor, Department of Pediatrics, University of Miami

M Akram Tamer, MD is a member of the following medical societies: American Medical Association and Florida Medical Association

Disclosure: Nothing to disclose.

Specialty Editor Board

John Gunn Lee, MD  Director of Pancreaticobiliary Service, Associate Professor, Department of Internal Medicine, Division of Gastroenterology, University of California at Irvine School of Medicine

John Gunn Lee, MD is a member of the following medical societies: American College of Gastroenterology, American College of Physicians, American Gastroenterological Association, and American Society for Gastrointestinal Endoscopy

Disclosure: Nothing to disclose.

Francisco Talavera, PharmD, PhD  Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Senior Pharmacy Editor, eMedicine

Disclosure: eMedicine Salary Employment

Simmy Bank, MD  Chair, Professor, Department of Internal Medicine, Division of Gastroenterology, Long Island Jewish Hospital, Albert Einstein College of Medicine

Disclosure: Nothing to disclose.

Alex J Mechaber, MD, FACP  Senior Associate Dean for Undergraduate Medical Education, Associate Professor of Medicine, University of Miami Miller School of Medicine

Alex J Mechaber, MD, FACP is a member of the following medical societies: Alpha Omega Alpha, American College of Physicians-American Society of Internal Medicine, and Society of General Internal Medicine

Disclosure: Nothing to disclose.

Chief Editor

Julian Katz, MD  Clinical Professor of Medicine, Drexel University College of Medicine; Consulting Staff, Department of Medicine, Section of Gastroenterology and Hepatology, Hospital of the Medical College of Pennsylvania

Julian Katz, MD is a member of the following medical societies: American College of Gastroenterology, American College of Physicians, American Gastroenterological Association, American Geriatrics Society, American Medical Association, American Society for Gastrointestinal Endoscopy, American Society of Law, Medicine & Ethics, American Trauma Society, Association of American Medical Colleges, and Physicians for Social Responsibility

Disclosure: Nothing to disclose.

References

  1. Salminen S, Isolauri E, Onnela T. Gut flora in normal and disordered states. Chemotherapy. 1995;41 suppl 1:5-15. [Medline].

  2. Marks MI. Infectious diarrhea: introduction and commentary. Pediatr Ann. Oct 1994;23(10):526-7. [Medline].

  3. Liebelt EL. Clinical and laboratory evaluation and management of children with vomiting, diarrhea, and dehydration. Curr Opin Pediatr. Oct 1998;10(5):461-9. [Medline].

  4. Hamer DH, Gorbach SL. Infectious diarrhea and bacterial food poisoning. In: Feldman M, Scharschmidt BF, Sleisenger MH, eds. Sleisinger and Fordtran's Gastrointestinaland Liver Disease. 6th ed. Philadelphia, Pa: WB Saunders; 1998:1594-1632.

  5. Steffen R, Collard F, Tornieporth N, et al. Epidemiology, etiology, and impact of traveler's diarrhea in Jamaica. JAMA. Mar 3 1999;281(9):811-7. [Medline]. [Full Text].

  6. Streit JM, Jones RN, Toleman MA, Stratchounski LS, Fritsche TR. Prevalence and antimicrobial susceptibility patterns among gastroenteritis-causing pathogens recovered in Europe and Latin America and Salmonella isolates recovered from bloodstream infections in North America and Latin America: report from the SENTRY Antimicrobial Surveillance Program (2003). Int J Antimicrob Agents. May 2006;27(5):367-75. [Medline].

  7. World Health Organization. Cholera: fact sheet no. 107. November 2008. Available at http://www.who.int/mediacentre/factsheets/fs107/en/. Accessed February 19, 2009.

  8. Lee LA, Gerber AR, Lonsway DR, et al. Yersinia enterocolitica O:3 infections in infants and children, associated with the household preparation of chitterlings. N Engl J Med. Apr 5 1990;322(14):984-7. [Medline].

  9. Centers for Disease Control and Prevention. Yersinia enterocolitica. October 25, 2005. Available at http://www.cdc.gov/ncidod/dbmd/diseaseinfo/yersinia_g.htm. Accessed February 18, 2009.

  10. Calbo E, Freixas N, Xercavins M, Riera M, Nicolás C, Monistrol O, et al. Foodborne nosocomial outbreak of SHV1 and CTX-M-15-producing Klebsiella pneumoniae: epidemiology and control. Clin Infect Dis. Mar 2011;52(6):743-9. [Medline].

  11. Cody SH, Abbott SL, Marfin AA, et al. Two outbreaks of multidrug-resistant Salmonella serotype typhimurium DT104 infections linked to raw-milk cheese in Northern California. JAMA. May 19 1999;281(19):1805-10. [Medline]. [Full Text].

  12. World Health Organization. Drug-resistant Salmonella: fact sheet no. 139. Revised April 2005. Available at http://www.who.int/mediacentre/factsheets/fs139/en/. Accessed February 19, 2009.

  13. Guandalini S, Pensabene L, Zikri MA, et al. Lactobacillus GG administered in oral rehydration solution to children with acute diarrhea: a multicenter European trial. J Pediatr Gastroenterol Nutr. Jan 2000;30(1):54-60. [Medline].

  14. Simakachorn N, Pichaipat V, Rithipornpaisarn P, et al. Clinical evaluation of the addition of lyophilized, heat-killed Lactobacillus acidophilus LB to oral rehydration therapy in the treatment of acute diarrhea in children. J Pediatr Gastroenterol Nutr. Jan 2000;30(1):68-72. [Medline].

  15. Duggan C, Nurko S. "Feeding the gut": the scientific basis for continued enteral nutrition during acute diarrhea. J Pediatr. Dec 1997;131(6):801-8. [Medline].

  16. Guandalini S, Dincer AP. Nutritional management in diarrhoeal disease. Baillieres Clin Gastroenterol. Dec 1998;12(4):697-717. [Medline].

  17. Sullivan PB. Nutritional management of acute diarrhea. Nutrition. Oct 1998;14(10):758-62. [Medline].

  18. [Best Evidence] Ruiz-Palacios GM, Perez-Schael I, Velazquez FR, et al, for the Human Rotavirus Vaccine Study Group. Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. N Engl J Med. Jan 5 2006;354(1):11-22. [Medline]. [Full Text].

  19. Garcia Rodriguez LA, Ruigomez A, Panes J. Acute gastroenteritis is followed by an increased risk of inflammatory bowel disease. Gastroenterology. May 2006;130(6):1588-94. [Medline].

  20. Cadle RM, Mansouri MD, Logan N, Kudva DR, Musher DM. Association of proton-pump inhibitors with outcomes in Clostridium difficile colitis. Am J Health Syst Pharm. Nov 15 2007;64(22):2359-63. [Medline].

  21. DuPont HL, The Practice Parameters Committee of the American College of Gastroenterology. Guidelines on acute infectious diarrhea in adults. Am J Gastroenterol. Nov 1997;92(11):1962-75. [Medline].

  22. Garcia Rodriguez LA, Ruigomez A, Panes J. Use of acid-suppressing drugs and the risk of bacterial gastroenteritis. Clin Gastroenterol Hepatol. Dec 2007;5(12):1418-23. [Medline].

  23. Gibreel A, Taylor DE. Macrolide resistance in Campylobacter jejuni and Campylobacter coli. J Antimicrob Chemother. Aug 2006;58(2):243-55. [Medline]. [Full Text].

  24. Kaur S, Vaishnavi C, Prasad KK, Ray P, Kochhar R. Comparative role of antibiotic and proton pump inhibitor in experimental Clostridium difficile infection in mice. Microbiol Immunol. 2007;51(12):1209-14. [Medline]. [Full Text].

  25. Mines D, Stahmer S, Shepherd SM. Poisonings: food, fish, shellfish. Emerg Med Clin North Am. Feb 1997;15(1):157-77. [Medline].

  26. Nataro JP, Steiner T, Guerrant RL. Enteroaggregative Escherichia coli. Emerg Infect Dis. Apr-Jun 1998;4(2):251-61. [Medline].

  27. Paterson DL. Resistance in gram-negative bacteria: Enterobacteriaceae. Am J Med. Jun 2006;119(6 suppl 1):S20-8; discussion S62-70. [Medline].

  28. Rodriguez LA, Ruigomez A. Increased risk of irritable bowel syndrome after bacterial gastroenteritis: cohort study. BMJ. Feb 27 1999;318(7183):565-6. [Medline]. [Full Text].

  29. Trachtman H, Christen E. Pathogenesis, treatment, and therapeutic trials in hemolytic uremic syndrome. Curr Opin Pediatr. Apr 1999;11(2):162-8. [Medline].

  30. Wong CS, Jelacic S, Habeeb RL, Watkins SL, Tarr PI. The risk of the hemolytic-uremic syndrome after antibiotic treatment of Escherichia coli O157:H7 infections. N Engl J Med. Jun 29 2000;342(26):1930-6. [Medline]. [Full Text].

 
Previous
Next
 
Table 1. Stool Characteristics and Determining Their Source
Stool CharacteristicsSmall BowelLarge Bowel
AppearanceWateryMucus and/or blood
VolumeLargeSmall
FrequencyIncreasedIncreased
BloodPossibly heme-positive but never gross bloodPossibly grossly bloody
pHPossibly < 5.5>5.5
Reducing SubstancesPossibly positiveNegative
WBC count< 5/HPFPossibly >10/HPF
Serum WBC countNormalPossible leukocytosis, bandemia
OrganismsPreformed toxins:



Bacillus species, Staphylococcus aureus



Invasive bacteria:



E coli and Shigella, Salmonella, Campylobacter, Yersinia, Aeromonas, and Plesiomonas species



Toxic bacteria:



E coli, cholera, C perfringens, Vibrio species, Listeria monocytogenes



Toxic bacteria:



C difficile



Other causes:



Rotavirus, Adenovirus, Calicivirus, Astrovirus, Norwalk virus, Giardia and Cryptosporidium species



Other causes:



Entamoeba species



Table 2. Organisms and Frequency of Symptoms
OrganismIncubationDurationVomitingFeverAbdominal Pain
Aeromonas speciesNone0-2 weeks+/-+/-No
Bacillus species1-16 hours1-2 daysYesNoYes
Campylobacter species2-4 days5-7 daysNoYesYes
C difficileVariableVariableNoFewFew
C perfringens0-11 dayMildNoYes
Enterohemorrhagic E coli1-8 days3-6 daysNo+/-Yes
Enterotoxigenic E coli1-3 days3-5 daysYesLowYes
Listeria species20 hours2 daysFewYes+/-
Plesiomonas speciesNone0-2 weeks+/-+/-+/-
Salmonella species0-3 days2-7 daysYesYesYes
Shigella species0-2 days2-7 daysNoHighYes
S aureus2-6 hours1 dayYesNoYes
Vibrio species0-1 days5-7 daysYesNoYes
Y enterocolitica0-61-46 daysYesYesYes
Table 3. Common Bacteria and Optimum Culture Media
OrganismDetection MethodMicrobiological Characteristics
Aeromonas speciesBlood agarOxidase-positive, flagellated GNB
Bacillus speciesBlood agarFacultatively aerobic, spore-forming GPR; beta-hemolytic; reduces nitrates; ferments carbohydrates
Campylobacter speciesSkirrow agarRapidly motile, curved GNR; Campylobacter jejuni 90% of infections, Campylobacter coli 5% of infections
C difficileCCFE agar, EIA for toxin, LA for proteinAnaerobic, spore-forming GPR; toxin-mediated diarrhea; produces pseudomembranous colitis
C perfringensNone availableAnaerobic, spore-forming GPR; toxin-mediated diarrhea
E coliMacConkey, EMB, or SM agarLactose-producing GNR
Listeria speciesBlood agarFlagellated GPB
Plesiomonas speciesBlood agarOxidase-positive GNR
Salmonella speciesBlood, MacConkey, EMB, XLD, or HE agarNonlactose, non–H2S-producing GNR
Shigella speciesBlood, MacConkey, EMB, XLD, or HE agarNonlactose and H2S-producing GNR; verotoxin (neurotoxin)
Staphylococcus speciesBlood agarHeat-stable, preformed toxin-mediated GPC
Vibrio speciesBlood or TCBS agarOxidase-positive, motile, curved GNB
Y enterocoliticaCIN agarNonlactose-producing, oval GNR
Previous
Next
 
 
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2012 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.